MA-EXCEL-DRYER
10.9.2020 21:18:12 CEST | Business Wire | Press release
After an exhaustive two-year process, a University of Arizona Health Sciences research team have announced the publication of their work, Comparison of electric hand dryers and paper towels for hand hygiene: a critical review of the literature . The review culled the current breadth of data, including published studies, news reports and online content, seeking to uncover which hand drying method, hand dryers or paper towels, is more hygienic and safer relative to human health risks. The researchers found that, while studies in the public arena generally favor paper towels over hand dryers, the conclusions are largely misleading and unsubstantiated.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200910005927/en/
Through the scientific research, the use of hand dryers and paper towels to dry hands were found to be equal from a health and safety perspective; the findings echo recommendations from the World Health Organization that everyone “frequently clean [their] hands…” and “dry [them] thoroughly by using paper towels or a warm air dryer,” and the Centers for Disease Control and Prevention that report that, “Both [clean towels or air hand dryers] are effective ways to dry hands.”
To conduct the study, the research team considered 293 papers and published studies for inclusion in their review, rejecting 270 for failing to meet review criteria or for reporting generalized recommendations without sufficient scientific evidence. The 23 peer-reviewed studies that met the inclusion criteria were categorized and prioritized based on their scientific rigor, a score determined by taking into account such factors as sample size, methodology, data quality and whether or not the study was set up to represent real-world scenarios.
The study that was found to have the highest rigor score was an independent study conducted by the Mayo Clinic, Effects of 4 Hand-Drying Methods for Removing Bacteria From Washed Hands: A Randomized Trial . It found that “…there is no difference in bacteria counts when drying with paper towels or hand dryers.” Only three studies received positive rigor scores for having realistic testing conditions, and none of the studies reported any negative effects of either hand drying method on human health.
Although numerous studies have been published evaluating the “best” method for hand drying, “best” has been defined in a variety of ways relative to bacterial removal efficacy, environmental contamination potentials, ecological or cost benefits, noise and more. Kelly Reynolds, MSPH, Ph.D., the corresponding author of the review explained that, “No study to date has examined the “best” drying method,” and that she and her team, “found no empirical data to support one hand drying method over another from a health and safety perspective.”
In light of the coronavirus pandemic, hand hygiene has been widely covered in the media. Reynolds shared that, “Media reports frequently used sensationalized headlines. While such headlines may increase traffic, they sometimes overgeneralize or exaggerate research results. Consumers may only read the headlines which can influence public opinion toward biased or erroneous conclusions.”
“At a time when proper hand washing and drying is of the utmost importance, exclusively recommending paper towels is limiting, and frankly, irresponsible,” said William Gagnon, vice president of marketing and sales at Excel Dryer. “Hand dryers provide an effective way to achieve completely dry hands, a critical part of proper hand hygiene, the top defense against the spread of germs, like coronavirus.”
The scoping review’s conclusion calls for future studies to examine the relationship between contamination that occurs due to hand-drying methods and human health outcomes. They offer that this can be accomplished by utilizing real-world scenarios while controlling certain variables.
“We hope these credible findings will be consulted as part of guidelines and reopening plans,” said William Gagnon, vice president of marketing and sales at Excel Dryer. “Sensationalized news accounts and click-bait headlines created an unsubstantiated concern around hand dryers and hygiene. We’re grateful to the researchers for uncovering the truth, and hope the findings will help to dispel myths and categorize hand dryers as the hygienic hand drying solution they are.”
About Excel Dryer, Inc.
Excel Dryer has been manufacturing the finest American-made hand dryers for more than 50 years. The family-owned and -operated company revolutionized the industry with the invention of the patented XLERATOR® Hand Dryer that created the high-speed, energy-efficient hand dryer category and set a new standard for performance, reliability and customer satisfaction. Excel Dryer prides itself on offering the best customer service and making hygienic, cost-effective and sustainable products people can depend on. Available for distribution worldwide, Excel Dryer products can be purchased through an established network of sales representatives who call on more than 5,000 distributors globally. Learn more about Excel Dryer at exceldryer.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200910005927/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
